ASX biotech share surges 20% higher on COVID-19 drug trial

The Mesoblast Limited (ASX: MSB) share price is surging higher today in response to news of a formal coronavirus drug trial.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price is surging higher today in response to news of a coronavirus drug trial. 

This morning, Mesoblast informed the ASX that it will begin formal trials for a product to treat patients suffering from COVID-19 within the coming weeks.

What trials will Mesoblast be conducting?

Mesoblast has announced that its allogeneic mesenchymal stem cell (MSC) product, remestemcel-L, will be evaluated in a randomised, placebo-controlled trial. The trial will be conducted as a private-public partnership in conjunction with the Cardiothoracic Surgical Trials Network (CTSN) on 240 patients with acute respiratory distress syndrome (ARDS) caused by COVID-19.

Commencement of the trial follows Mesoblast's approved application for an Investigational New Drug (IND) from the US Food and Drug Administration (FDA) earlier this week. With the coronavirus pandemic moving quickly in the US, the FDA was quick to approve Mesoblast's investigational study as the product is already in a number of clinical trials for inflammatory conditions.

How does Mesoblast's product help patients with COVID-19?

The COVID-19 virus has a detrimental impact on the lungs of patients by initiating an overproduction of immune cells. The virus creates a 'cytokine storm' which results in immune cells flooding the lungs, causing substantial inflammation and a build-up of fluid that can result in death. As a result, patients suffer from ARDS and are admitted to intensive care units to receive oxygen ventilation. According to the company's update, the mortality rate of patients with ARDS as a result of COVID-19 is as high as 80%.

Mesoblast's remestemcel-L product is design to counteract the inflammatory process by neutralising the production of pro-inflammatory cytokines and promoting the production of anti-inflammatory cytokines.  Remestemcel-L was already in a number of other clinical trials targetted at reducing inflammatory conditions on patients with steroid-refractory acute graft versus host disease (aGVHD).

Foolish takeaway

Mesoblast is a world leader in developing regenerative medicines for inflammatory diseases and has prided itself on innovation in stem cell research. The company has used its cell therapy technology to establish a broad portfolio of commercial products and has a large pipeline of therapies in late-stage development and testing.

If proven effective against ARDS in COVID-19 patients, the product could save thousands and thousands of lives and would be monumental for medical science and biotechnology in Australia.

The Mesoblast share price has surged more than 55% since receiving approval from the FDA earlier this week and is currently trading 20.16% higher today, having hit an intra-day high of $2.21.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »